![Dextromethorphan/Bupropion: A Novel Oral NMDA (N-methyl-d-aspartate) Receptor Antagonist with Multimodal Activity | CNS Spectrums | Cambridge Core Dextromethorphan/Bupropion: A Novel Oral NMDA (N-methyl-d-aspartate) Receptor Antagonist with Multimodal Activity | CNS Spectrums | Cambridge Core](https://static.cambridge.org/binary/version/id/urn:cambridge.org:id:binary:20190928053113541-0005:S1092852919001470:S1092852919001470_fig4g.jpeg?pub-status=live)
Dextromethorphan/Bupropion: A Novel Oral NMDA (N-methyl-d-aspartate) Receptor Antagonist with Multimodal Activity | CNS Spectrums | Cambridge Core
![Dextromethorphan/Bupropion: A Novel Oral NMDA (N-methyl-d-aspartate) Receptor Antagonist with Multimodal Activity | CNS Spectrums | Cambridge Core Dextromethorphan/Bupropion: A Novel Oral NMDA (N-methyl-d-aspartate) Receptor Antagonist with Multimodal Activity | CNS Spectrums | Cambridge Core](https://static.cambridge.org/binary/version/id/urn:cambridge.org:id:binary:20190928053113541-0005:S1092852919001470:S1092852919001470_fig1g.jpeg?pub-status=live)
Dextromethorphan/Bupropion: A Novel Oral NMDA (N-methyl-d-aspartate) Receptor Antagonist with Multimodal Activity | CNS Spectrums | Cambridge Core
![Bupropion Inhibits Serotonin Type 3AB Heteromeric Channels at Clinically Relevant Concentrations | Molecular Pharmacology Bupropion Inhibits Serotonin Type 3AB Heteromeric Channels at Clinically Relevant Concentrations | Molecular Pharmacology](https://molpharm.aspetjournals.org/content/molpharm/97/3/171/F1.large.jpg)
Bupropion Inhibits Serotonin Type 3AB Heteromeric Channels at Clinically Relevant Concentrations | Molecular Pharmacology
![A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor. - Abstract - Europe PMC A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor. - Abstract - Europe PMC](https://europepmc.org/articles/PMC514842/bin/i1523-5998-6-4-159-f01.jpg)
A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor. - Abstract - Europe PMC
![Naltrexone/bupropion for obesity: An investigational combination pharmacotherapy for weight loss - ScienceDirect Naltrexone/bupropion for obesity: An investigational combination pharmacotherapy for weight loss - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1043661814000449-fx1.jpg)
Naltrexone/bupropion for obesity: An investigational combination pharmacotherapy for weight loss - ScienceDirect
![Pharmacological and Neurotoxicological Actions Mediated By Bupropion and Diethylpropion - ScienceDirect Pharmacological and Neurotoxicological Actions Mediated By Bupropion and Diethylpropion - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0074774209880094-gr1.jpg)